AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00537394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine
Description: Two 100-mg tablets twice daily
Study NCT00537394 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Etravirine
Description: Two 100-mg tablets twice daily
Study NCT00537394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Dosage dependent on regimen in which maraviroc is included
Study NCT00537394 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Maraviroc
Description: Dosage dependent on regimen in which maraviroc is included
Study NCT04517123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone Positioning
Description: Prone Positioning
Study NCT04357743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chin supported Arm ergometry with pursed lip breathing
Description: The participants sat in chin support position for 10 minutes followed by arm ergometry with pursed lip breathing for 10 minutes. The participants again sat in chin support position for 10 minutes.~The treatment was provided for one week
Study NCT04357743 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm ergometry with pursed lip breathing
Description: The participants sat in normal position for 10 minutes followed by arm ergometry with pursed lip breathing for 10 minutes; the participants again sat in sitting position for 10 minutes.~The treatment was provided for one week.
Study NCT01623102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin and gemcitabine combination with Bevacizumab
Description: Patients receive gemcitabine and cisplatin chemotherapy combined with Bevacizumab every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Gemcitabine 1250mg/m2 d1, d8, cisplatin 75mg/m2 d1, Bevacizumab 7.5 mg / kg every 21 days.
Study NCT01623102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine combined with cisplatin chemotherapy
Description: Patients receive gemcitabine combined with cisplatin chemotherapy every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Gemcitabine 1250mg/m2 d1, d8, + cisplatin 75mg/m2 d1.
Study NCT03611738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: Ceritinib daily by mouth (PO) with food, according to the dosage schedule outlined in the treatment arm.
Study NCT03611738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel intravenously (IV) every 3 weeks, according to the dosage schedule outlined in the treatment arm.
Study NCT01468285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: betahistine dihydrochloride
Description: betahistine dihydrochloride 24 mg tablet b.i.d. six weeks treatment
Study NCT01468285 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablets b.i.d., six weeks treatment
Study NCT03631602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antifungal prophylaxis
Description: posaconazole oral suspension vs itraconazole oral solution
Study NCT03631602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antifungal prophylaxis
Description: posaconazole oral suspension vs itraconazole oral solution
Study NCT00784563 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuous training
Description: The maximal heart rate (HRmax) in the exercise prescription was based on age\[Goldberg, Elliot, and Kuehl1988\] and reduced by 20% in participants who used beta-blockers.\[Wonisch et al. 2003\] The duration of exercise sessions (3x/week) was advanced from 15 to 45 minutes over the first 6 weeks. The goal for continuous training was to remain within 70-80% of HRmax throughout the session.
Study NCT00784563 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interval training
Description: Interval trainees alternated every 3 minutes between slower (60-70% of HRmax) and faster (80-90% of HRmax) walking \[Wisloff et al. 2007\].
Study NCT03404817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Original formulation EMB-001
Description: Single oral dose (720 mg metyrapone/24 mg oxazepam)
Study NCT03404817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: New formulation EMB-001
Description: Single oral dose (720 mg metyrapone/24 mg oxazepam)
Study NCT02228681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10mg daily by mouth
Study NCT02228681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 20 mg daily by mouth on alternating weeks (even numbered) weeks
Study NCT01780181 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy
Description: treated with single-agent chemotherapy :DOC、NVB、GEM DOC 60mg/m2 d1 Q3W NVB 30mg/m2 d1，d8 Q3W GEM 1200mg/m2 d1，d8 Q3W
Study NCT02458703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise test
Description: Subjects will have the test in the Exercise Suite of Hammersmith Hospital, London, UK. They will have painless skin probes placed on their fingers, chest, and legs to monitor heart rate, ECG, blood oxygen levels, and oxygen delivery during the test. Subjects will also be shown how to breathe through a mouthpiece with a nose clip on, and how to indicate on a sliding device whether they feel breathless. They will then start cycling against a very low resistance at a steady speed. As long as they feel comfortable, there will be a gradual increase in work load until they feel they cannot keep going at the same speed. They can also stop sooner for any reason. Afterwards, while they are cooling down, they will fill in a short questionnaire describing how they feel. 20-30mls of blood will be taken for analysis.
Study NCT03819998 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of Fetuin-A level in serum
Description: Fetuin A level will be measured in blood of the PCOS women
Study NCT02228681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5mg once a day by mouth
Study NCT02228681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medroxyprogesterone Acetate
Description: 200 mg daily by mouth
Study NCT02060721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Macitentan 10mg, oral tablet, once daily
Study NCT03405220 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self affirmation, 10 items, written examples
Description: Participants will complete the 10 item self-affirmation kindness quiz and will be asked to provide written examples for each item they respond yes to.
Study NCT03405220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self affirmation, 10 items, no examples
Description: Participants will complete the 10 item self-affirmation kindness quiz and will not be asked to provide examples for any items they respond yes to.
Study NCT03405220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self affirmation, 10 items, imagined examples
Description: Participants will complete the 10 item self-affirmation kindness quiz and will be asked to imagine examples for each item they respond yes to.
Study NCT03405220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self affirmation, 5 items, written examples
Description: Participants will complete a 5 item self-affirmation kindness quiz and will be asked to provide written examples for each item they respond yes to.
Study NCT03405220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self affirmation, 5 items, no examples
Description: Participants will complete a 5 item self-affirmation kindness quiz and will not be asked to provide examples for any items they respond yes to.
Study NCT03405220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self affirmation, 5 items, imagined examples
Description: Participants will complete a 5 item self-affirmation kindness quiz and will be asked to imagine examples for each item they respond yes to.
Study NCT03405220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self affirmation, 3 items, written examples
Description: Participants will complete a 3 item self-affirmation kindness quiz and will be asked to provide written examples for each item they respond yes to.
Study NCT03405220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self affirmation, 3 items, no examples
Description: Participants will complete a 3 item self-affirmation kindness quiz and will not be asked to provide examples for any items they respond yes to.
Study NCT03405220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self affirmation, 3 items, imagined examples
Description: Participants will complete a 3 item self-affirmation kindness quiz and will be asked to imagine examples for each item they respond yes to.
Study NCT03638453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PediCARE
Description: PediCARE provides support for groceries (using an online grocery delivery service called Instacart) and transportation to and from the hospital (using rides through RideHealth).
Study NCT03638453 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard care per hospital guidelines.
Study NCT04412863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection
Study NCT04412863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon-alfa 2a
Description: pegylated interferon-alfa 2a given by subcutaneous injection
Study NCT03901274 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness
Description: The Wellness framework packages together evidence-based practices of family engagement, modular evidence-based practice, quality assurance, and implementation support. Depending on their time of enrollment, participants can be involved in this condition for one to three years. They will be asked to complete assessments during their therapy sessions periodically throughout the trial.
Study NCT03901274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partnership
Description: The two patient-centered enhancements are: enhancing mental health literacy and stigma reduction, and improving family-school-mental health partnerships. Depending on their time of enrollment, participants can be involved in this condition for one to three years. They will be asked to complete assessments during their therapy sessions periodically throughout the trial.
Study NCT00286728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive referral to dual-focused self-help
Description: 4 group sessions to introduce patients to dual focused groups
Study NCT04545749 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-612
Description: UB-612 is a proprietary high-precision designer S1-RBD-protein based vaccine incorporating a Th/CTL epitope peptide pool which could bind to human MHC-I and MHC-II to activate T cells.
Study NCT01404819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesia with Xenon
Description: Patients undergo anesthesia with xenon (remifentanil with xenon).
Study NCT01404819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard anesthesia
Description: Patients undergo standard anesthesia (remifentanil with propofol)
Study NCT03340389 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: a ray-tracing aberrometry
Description: The Dysfunctional Lens Index is obtained by a ray-tracing aberrometry
Study NCT03210558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone cream 1% (Andro-Feme® )
Description: Testosterone cream 10 mg (1 ml) daily, supplied every evening via a dose applicator to the upper outer thigh for 10 weeks.
Study NCT03210558 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: Placebo cream (1 ml) daily, supplied every evening via a dose applicator to the upper outer thigh for 10 weeks.
Study NCT02547181 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Modification
Description: Patient will be provided with tensor bandage and instructed on specific behaviors to prevent movement of the injured part of the hand.
Study NCT02547181 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Splint
Description: fibreglass splint
Study NCT02916186 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acellular Dermal Matrix
Description: Puros Dermis is a collagenous membrane derived from solvent preserved,human dermis, works as biological scaffold for the new formation of vasculated connective tissue.
Study NCT02916186 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Acellular Dermal Matrix
Description: Puros Dermis is a collagenous membrane derived from solvent preserved,human dermis, works as biological scaffold for the new formation of vasculated connective tissue.
Study NCT02916186 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tunnel technique with the subepithelial connective tissue graft
Description: Tunnel prepared with the placement of subepithelial connective tissue graft harvested from the palate
Study NCT02916186 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tunnel technique with the subepithelial connective tissue graft
Description: Tunnel prepared with the placement of subepithelial connective tissue graft harvested from the palate
Study NCT01506596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle. Study treatment may continue until disease progression or unacceptable toxicity.
Study NCT00771758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxycodone IR
Description: maximum daily dose 450 mg
Study NCT00771758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 5 or 10 mg capsule every 4 - 6 hr as needed for up to 10 days
Study NCT00771758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tapentadol IR
Description: 50 or 75 mg capsule every 4 - 6 hr as needed for up to 10 days
Study NCT03045744 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: long-term paired associative stimulation
Description: Paired associative stimulation (PAS) administered 3 times per week. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
Study NCT03310138 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Real Transcranial Magnetic Stimulation
Description: Transcranial magnetic stimulation (TMS) is a minimally invasive brain stimulation technology that can focally stimulate the brain of an awake individual. A localized pulsed magnetic field transmitted through a figure-8 coil (lasting only microseconds) is able to focally stimulate the cortex by depolarizing superficial neurons, which induces electrical currents in the brain. TMS pulses that are delivered repetitively and rhythmically are referred to as repetitive TMS (rTMS). In this study TMS is being delivered with the MagVenture MagPro B60 coil.
Study NCT03310138 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Description: The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
Study NCT03729453 — intervention group
Intervention type: DEVICE
Intervention: SpyGlass
Description: Visualization of main pancreatic duct with SpyGlass catheter.
Study NCT00829426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam Extended-Release 3 mg Tablets
Description: 1 x 3 mg, single dose fasting
Study NCT00829426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam Extended-Release 3 mg Tablets
Description: 1 x 3 mg, single dose fasting
Study NCT04767659 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAMMOT2
Description: Breast cancer patients candidate for neoadjuvant chemotherapy will be evaluated with optical imaging prior to commencement of NAC/baseline, 2-5 days post-NAC, 6-8 days post-NAC, 2 weeks post-NAC, half-way through and on completion of NAC. 2 additional optical evaluations will be carried out on the first 5 patients enrolled, one before breast biopsy and one after the positioning of the metallic clip, in order to evaluate the potential artefacts related to these procedures.
Study NCT03924661 — intervention group
Intervention type: DEVICE
Intervention: Aortic Valve Replacement
Description: SJM™ Masters Series Hemodynamic Plus (HP) 15mm aortic mechanical heart valve as a replacement device for patients with a diseased, damaged, or malfunctioning aortic valve
Study NCT03674528 — intervention group
Intervention type: OTHER
Intervention: Magnetic Resonance Elastography (MRE)
Description: The MRE scan will several breath holds and will take approximately 30 minutes to complete.
Study NCT03674528 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Liver biopsy
Description: Subjects undergoing WLS will be asked to allow for liver biopsy samples to be collected during their surgical procedure. The collection of these samples will take approximately 5 minutes to complete.
Study NCT01702207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Once Daily Tacrolimus
Description: Subjects switched from the tacrolimus twice daily (Prograf®) to the once daily formulation (Advagraf®) to maintain a trough tacrolimus level of 5-8.
Study NCT01702207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Twice Daily Tacrolimus
Description: Subjects are kept on Prograf® which is the Twice Daily Tacrolimus
Study NCT02010892 — intervention group
Intervention type: PROCEDURE
Intervention: Stent Grafting (ESR)
Study NCT02010892 — intervention group
Intervention type: PROCEDURE
Intervention: Open Surgery (OSR)
Study NCT04471909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEXUS Aortic Stent Graft System
Description: Arch Stent Graft, whose cranial narrow end is intended to be deployed into the Brachiocephalic artery and whose distal end is intended to be deployed into the Descending Thoracic Aorta.~Ascending Stent Graft intended to be deployed in the Ascending Aorta.~OPTIONAL: Descending Extension can be used in case the aortic lesion elongates further distally and out of the covered length offered by the Arch Stent Graft. Multiple Descending Extensions can be used if needed to cover the entire length of the lesion.
Study NCT01181427 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABT-267
Description: See arm description
Study NCT01181427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-267
Description: See arm description
Study NCT01181427 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See arms description
Study NCT04706208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Multisensory Therapy
Description: Cognitive multisensory rehabilitation (CMR) is a type of physical therapy that incorporates conscious perception of body positions and movements during (multi)sensory discrimination exercises. The treating therapists will give 40 minutes of discrimination exercises embedded in functional movements followed by 5 minutes of applying the learned strategies during activities of daily living. CMR uses several types of discrimination exercises: Participants discriminated shapes, length, weight, distance, resistance, textures or compare kinesthetic information with visual information for integration of multisensory information. Solving the discrimination task is combined with reflection and a learning process, prompted by the therapist on how the limb (was) moved or was positioned.
Study NCT04706208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Standard of care treatment for neuropathic pain after spinal cord injury
Study NCT04706208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Assessment
Description: Clinical assessments are detailed below. Screening will include demographic and general health data; mini mental state evaluation (MMSE)-short version; Edinburgh handedness inventory; and the kinesthetic and visual imagery questionnaire (KVIQ).
Study NCT04706208 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Clinical Assessment
Description: Clinical assessments are detailed below. Screening will include demographic and general health data; mini mental state evaluation (MMSE)-short version; Edinburgh handedness inventory; and the kinesthetic and visual imagery questionnaire (KVIQ).
Study NCT04706208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: The MRI scanning will include structural scans, resting-state functional MRI, and 4 task-based functional MRI.
Study NCT04706208 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: The MRI scanning will include structural scans, resting-state functional MRI, and 4 task-based functional MRI.
Study NCT04706208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OPTIONAL: blood draw
Description: This part is OPTIONAL: 38ml of blood will be taken one time (for able body adults) or at 3 time points (for adults with spinal cord injury and neuropathic pain.
Study NCT04706208 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: OPTIONAL: blood draw
Description: This part is OPTIONAL: 38ml of blood will be taken one time (for able body adults) or at 3 time points (for adults with spinal cord injury and neuropathic pain.